Search This Site:
Clinical Commissioning Groups Logo

Joint Formulary Newsletter

Bedfordshire and Luton Joint Formulary Newsletter

March 2020, Number 3

Incorporates Key Recommendations from The Bedfordshire and Luton Joint Prescribing Committee (JPC) 26th February 2020

FORMULARY UPDATE

The Bedfordshire and Luton Joint Formulary (a combined medicines formulary for use by BCCG, LCCG, Bedford Hospital and the Luton and Dunstable University Hospital) is now ‘live’. It can be accessed here

Unless otherwise stated decisions made apply to all organisations in the Joint Formulary Group.

FORMULARY TRAFFIC LIGHT STATUS INFORMATION
RED RED - Hospital Only - to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment
AMBER Amber medicines are considered suitable for GP prescribing following specialist initiation
GREEN These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations
SCG Shared Care - These medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place, status reverts to RED.
BLACK A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. DO NOT PRESCRIBE
The following ADDITIONS to the Joint Formulary were agreed at the JPC Committee Meeting

No new medicines were added at this meeting

Hospital Drug and Therapeutic Committee Updates

Luton and Dunstable Hospital DTC
Humalog Junior Quickpen – added to formulary as an option for children who require a device which measures in 0.5 units.

CCG Prescribing Committees

BCCG Prescribing Committee

  • Hanixol® 50mg – mercaptopurine branded generic
Wound Care Formulary Group (Ratified by the JPC)

No update from the Wound Care Group

Decisions Made By Joint Formulary Group (Ratified by the JPC)
  • Midodrine to be added to formulary
  • Riluzole entry updated to show no longer HCD and amend to Amber shared care
  • Riluzole liquid added to formulary as per SCG
  • Spiriva handihaler – no longer listed as ‘first choice’ as per COPD guideline
  • Diprosalic scalp application – Added to formulary
  • Ketamine amber SCG – palliative hospice
  • Fidaxomicin – Change net formulary entry to reflect community antimicrobial guideline, only to be prescribed by GPs on the advice of a microbiologist
  • Fluticasone nasal spray – added
  • Colomycin nebulised 2MU strength Added – for non CF patients
  • RMOC guidance on prescribing vitamin B compound in alcoholism has been adopted by the Joint Formulary Group. Vitamin B compound strong is now restricted to a 10 course for refeeding syndrome.
NICE Updates

Join Formulary updates following publication of NICE Technology Appraisal Guidance.

CCG Commissioned
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Technology appraisal guidance [TA617] Published date: 08 January 2020 https://www.nice.org.uk/guidance/ta617

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations will be less than £5 million per year in England (or £9,000 per 100,000 population).
The technology is a further treatment option and due to this the overall incremental cost of treatment is not deemed to be significant.
JPC Action – added to Joint Formulary (new drug created and NICE link added).

Sotagliflozin with insulin for treating type 1 diabetes, Technology appraisal guidance [TA622] Published date: 12 February 2020, https://www.nice.org.uk/guidance/ta622
JPC Action – To add to formulary and confirm any additional implementation actions when the product is launched.

Patiromer for treating hyperkalaemia, Technology appraisal guidance [TA623] Published date: 13 February 2020, https://www.nice.org.uk/guidance/ta623
JPC Action – add to Formulary – Proposed amber, Specialist Initiation with GP to continue (for patients with persistent hyperkalemia) and red (hospital only) for emergency treatment of hyperkalaemia. Further guidance to be issued on the level of information to be provided to GPs to enable them to take over prescribing.

NICE CCG Commissioned Appraisal withdrawn (Monday 10th February 2020):-
Collagenase clostridium histolyticum (CCH) for treating Dupuytren’s contracture (TA459)

NHSE Commissioned- New drugs added
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome, Technology appraisal guidance [TA614] Published date: 18 December 2019. https://www.nice.org.uk/guidance/ta614JPC Action – added to Joint Formulary (created and link added) – Hospital Only Prescribing.

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome, Technology appraisal guidance [TA615] Published date: 18 December 2019, https://www.nice.org.uk/guidance/ta615JPC Action – added to Joint Formulary (created and link added) – Hospital Only Prescribing.

Cladribine for treating relapsing–remitting multiple sclerosis, Technology appraisal guidance [TA616] Published date: 19 December 2019
https://www.nice.org.uk/guidance/ta616JPC Action – link added to Joint Formulary – Hospital Only Prescribing.

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer.
Technology appraisal guidance [TA619] Published date: 15 January 2020. https://www.nice.org.uk/guidance/ta619JPC Action – Link added to Joint Formulary and TA information amended.

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Technology appraisal guidance [TA620] Published date: 15 January 2020. https://www.nice.org.uk/guidance/ta620 – JPC Action – Link added to Joint Formulary and TA information amended.

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis, Technology appraisal guidance [TA624] Published date: 19 February 2020, https://www.nice.org.uk/guidance/ta624 – recommended – JPC Action – link added to Joint Formulary

Scroll to Top